EGF vs Rigin

Binds EGFR (EGF receptor / ErbB1), activating RAS/MAPK and PI3K/Akt signaling cascades. Promotes keratinocyte and fibroblast proliferation, accelerates wound re-epithelialization, and stimulates collagen and hyaluronic acid production.

Epidermal growth factor (EGF) is an endogenous 53-amino-acid polypeptide that binds the EGF receptor (EGFR) to stimulate cell proliferation, migration, and differentiation in epithelial and mesenchymal cells; it plays a fundamental role in wound healing, skin regeneration, and tissue repair by promoting keratinocyte and fibroblast activation through tyrosine kinase-mediated downstream signaling. EGF activates EGFR tyrosine kinase to initiate PI3K/Akt and MAPK/ERK proliferative signaling cascades; in wound contexts, topically applied recombinant EGF accelerates epithelialization and granulation tissue formation, and injectable EGF has been evaluated for wound bed preparation in diabetic and chronic wounds. Clinical trials of recombinant human EGF for wound healing — including a PubMed-indexed human clinical trial in diabetic foot ulcers — have demonstrated improvements in wound closure and tissue regeneration; recombinant EGF preparations are approved in some countries (Cuba, South Korea) for diabetic wound healing under prescription conditions. Topically applied EGF has no FDA approval in the United States for wound healing or cosmetic applications; recombinant EGF-based wound therapeutics are available internationally under national regulatory approvals outside the US, and EGF is widely incorporated into cosmetic formulations at concentrations where receptor activation and clinical benefit have not been independently validated.

Palmitoylated tetrapeptide mimicking IgG C-terminal sequence; reduces IL-6 production in keratinocytes; combined with Matrixyl (Pal-GHK) forms Matrixyl 3000; anti-inflammatory and skin matrix support

Rigin (Palmitoyl Tetrapeptide-7) is a synthetic cosmetic peptide developed to address skin inflammation and age-related matrix degradation. It is proposed to suppress interleukin-6 (IL-6), a cytokine associated with chronic low-grade skin inflammation that accelerates extracellular matrix breakdown. Evidence for rigin is primarily derived from manufacturer-sponsored in vitro and ex vivo cosmetic research; no independent peer-reviewed clinical trials have been identified in indexed biomedical literature. Rigin is a cosmetic ingredient developed by Sederma/Croda; its evidence base consists of manufacturer-sponsored studies only and it has not been evaluated by regulatory agencies for any medicinal claim. Rigin and Matrixyl 3000 Rigin (Palmitoyl Tetrapeptide-7, Pal-GQPR) is one of two peptide actives in Sederma's Matrixyl 3000 formulation — the other being Matrixyl (palmitoyl pentapeptide-4, Pal-KTTKS). In the Matrixyl 3000 combination, the two peptides are proposed to address complementary aspects of skin aging: Matrixyl (Pal-KTTKS) stimulates new collagen I and III synthesis via TGF-β signaling; Rigin (Pal-GQPR) suppresses IL-6-mediated matrix degradation, reducing the rate at which newly synthesised collagen is broken down. The combination therefore targets both the anabolic (synthesis) and anti-catabolic (degradation prevention) sides of collagen matrix maintenance. This mechanistic pairing is the basis for the "3000" formulation's improved efficacy claims relative to the original single-peptide Matrixyl. In cosmetic formulations, Rigin is listed under its INCI name (Palmitoyl Tetrapeptide-7) and appears alongside palmitoyl pentapeptide-4 in products marketed as containing Matrixyl 3000. Typical concentration in the final product is in the range of 4–8% of the Sederma Matrixyl 3000 concentrate, which itself contains the peptides at a defined dilution. Rigin is a topical cosmetic ingredient — it has no injectable or clinical pharmaceutical application and does not require a prescription in any jurisdiction.